PT-141 (bremelanotide) is a synthetic melanocortin-receptor agonist that acts inside the brain rather than on penile or vaginal blood vessels, which is why it became a reference tool for studying the central neurobiology of sexual desire and arousal. This article reviews what the peptide is, how the melanocortin pathway is thought to work, and what the human and preclinical literature actually shows.

Why the central pathway drew attention

Sexual dysfunction is common and, on a population level, growing. A widely cited projection based on the Massachusetts Male Aging Study estimated that the worldwide prevalence of erectile dysfunction (ED) would rise from roughly 152 million men in 1995 to approximately 322 million by 2025, with the largest increases in aging populations across Africa, Asia, and South America.¹ The dominant pharmacology that emerged for ED — phosphodiesterase type-5 (PDE-5) inhibitors such as sildenafil — works peripherally, enhancing nitric-oxide/cyclic-GMP signaling in penile vascular smooth muscle. That approach does not directly address the parts of sexual response that originate in the brain: motivation, desire, and central arousal.

A subset of research subjects respond only partially to peripheral agents, and desire disorders in women were not addressed by vasodilatory drugs at all. This gap is what made the melanocortin system scientifically interesting. Reviews of the field describe melanocortin agonists as a route to investigate top-down components of arousal that peripheral vasodilators leave untouched.⁶ PT-141 became the most clinically studied tool in that line of inquiry.

What PT-141 is: structure and receptor pharmacology

PT-141, known generically as bremelanotide, is a cyclic heptapeptide analog of α-melanocyte-stimulating hormone (α-MSH). It is the carboxylate derivative of melanotan II (MT-II), the earlier non-selective “superpotent” melanocortin agonist.² Researchers working with the parent scaffold often keep melanotan II on hand as a comparison ligand when characterizing melanocortin-receptor pharmacology.

The melanocortin system comprises five receptor subtypes (MC1R–MC5R). PT-141 acts as an agonist principally at MC3R and MC4R, the two subtypes expressed most heavily in the central nervous system.³ MC1R governs pigmentation, MC2R mediates adrenal corticosteroid signaling, and MC5R is associated with exocrine function; the relative selectivity of a given melanocortin ligand across these subtypes shapes both its intended central effects and its off-target signals. Which of the two central receptors principally drives sexual response has been debated in the literature. The MC4R is generally described as the primary effector, while the role of MC3R remains less well characterized, and some laboratory data suggest forebrain MC3R antagonism may even enhance melanocortin-induced erections.²

The central mechanism of sexual-response modulation

The core hypothesis is that PT-141 modulates sexual response by activating melanocortin receptors on neurons in the hypothalamus and connected limbic and reward-related regions, rather than by acting on genital vasculature. Systemic administration of PT-141 to rats increases c-Fos immunoreactivity — a marker of neuronal activation — in hypothalamic regions, and neurons in those same regions take up pseudorabies virus injected into the penile corpus cavernosum, tracing an anatomical link between central melanocortin-responsive cells and the peripheral erectile apparatus.⁴

Mechanistic reviews place the paraventricular nucleus of the hypothalamus at the center of this circuitry, with melanocortin signaling proposed to engage downstream dopaminergic and oxytocinergic pathways that regulate arousal and copulatory behavior.⁶ Investigators studying the female side of the model similarly frame bremelanotide as acting on central desire and arousal circuits, distinct from the peripheral vascular action of PDE-5 inhibitors.⁵ Any peripheral nitric-oxide involvement is generally treated as secondary to, and downstream of, the central melanocortin event rather than the primary site of action.

An important caveat is that the fine-grained circuitry — exact receptor localization, the balance of MC3R versus MC4R contributions, and the identity of the downstream transmitters — is still an active research question. The pseudorabies and c-Fos data establish anatomical and activational plausibility; they do not fully resolve the mechanism.

Preclinical models

Before human work, melanocortin agonists were shown to induce penile erections across several species, including non-human primates, following systemic administration.⁵ In rodent models, pre-copulatory behaviors in female rats that are treated as analogues of sexual arousal were evoked by melanocortin agents, and the erectogenic effect in males was mapped to central rather than peripheral sites.⁷ These animal models remain the standard setting for observing melanocortin-driven neural and behavioral outcomes under controlled conditions, and they are where questions about receptor subtype selectivity are most tractable.

The translational logic that carried the compound forward was that a centrally acting agonist could, in principle, influence desire and motivation — endpoints that peripheral vasodilators cannot reach — and that it might do so in subjects who respond poorly to existing peripheral agents.

Human evidence in men (erectile dysfunction)

Early human studies used intranasal delivery. In healthy male volunteers and men with mild-to-moderate ED, a single intranasal dose produced a statistically significant erectile response versus placebo at doses above 7 mg, with the first erection typically beginning around 30 minutes after administration and a plasma half-life of roughly 2 hours.⁸ Flushing and nausea were the most frequently reported adverse events, and no maximum tolerated dose was identified in those studies.

A subcutaneous formulation was then evaluated. In healthy men, subcutaneous PT-141 produced statistically significant erectile responses at doses above 1.0 mg; in men who reported an inadequate response to sildenafil, doses of 4 and 6 mg produced significant erectile responses in the presence of visual sexual stimulation.⁹ This observation — activity in PDE-5 non-responders — is frequently highlighted in the literature because it is consistent with a mechanism that operates upstream of the peripheral vascular step. It is important to state plainly, however, that development for male ED did not proceed to approval; the compound is not an approved treatment for men.

Human evidence in women (HSDD)

The most substantial human data concern premenopausal women with hypoactive sexual desire disorder (HSDD). A small early crossover study using a single intranasal dose in women with female sexual arousal disorder reported that more women described moderate-to-high desire after bremelanotide than after placebo, although an objective measure of vaginal vasocongestion did not change significantly.³ A subsequent randomized, placebo-controlled, dose-finding phase 2 trial in premenopausal women reported statistically significant improvements versus placebo on the Female Sexual Function Index (FSFI) and reductions on the Female Sexual Distress Scale (FSDS-DAO), pooling the 1.25/1.75 mg subcutaneous doses.¹⁰ A companion phase 2b responder analysis established minimal clinically important differences for those endpoints and found that responder rates at 1.75 mg reached statistical significance versus placebo.¹¹

The pivotal evidence came from two identical phase 3 trials (RECONNECT). Across 1,267 randomized premenopausal women, subcutaneous bremelanotide 1.75 mg taken as needed produced statistically significant increases in the FSFI-desire domain and statistically significant reductions in desire-related distress versus placebo over 24 weeks; the most common adverse events were nausea, flushing, and headache.¹² It is worth noting that the absolute effect sizes on the desire domain were modest (integrated change of about 0.35 points), and that the coprimary distress and desire endpoints, while statistically significant, reflect patient-reported scales rather than physiological arousal measures.

How it compares with PDE-5 inhibitors

The clearest way to summarize PT-141's research profile is against the peripheral vasodilator class it was contrasted with. Reconstitution for laboratory handling typically uses bacteriostatic water; the comparison below concerns mechanism and observed research endpoints, not any use recommendation.

Because the two classes act at different points in the pathway, the research literature has treated them as complementary probes rather than as interchangeable. The melanocortin route allows examination of desire, motivation, and distress; the vasodilatory route addresses tissue rigidity. Reviews of melanocortin-receptor agonists explicitly frame the value of the class as expanding investigation into central mechanisms alongside, rather than replacing, peripheral pharmacology.⁵

Safety observations and regulatory status

The best-characterized cardiovascular signal is a small, transient rise in blood pressure. Ambulatory blood-pressure monitoring in 397 premenopausal women found increases in systolic blood pressure of roughly 2.4–3.2 mmHg relative to placebo in the hours after dosing, accompanied by modest reductions in heart rate; peak increases generally lasted under 15 minutes.¹³ This finding is mechanistically consistent with MC4R engagement and is why later trials incorporated in-clinic blood-pressure monitoring.

A safety review spanning the full clinical development program (about 3,500 subjects across 43 studies) reported that the most common adverse events were nausea, flushing, headache, and injection-site reactions, that these were mostly mild to moderate, and that nausea was the leading reason for discontinuation.¹⁴ Focal hyperpigmentation was rare with as-needed dosing but occurred in more than a third of subjects following up to 16 consecutive daily doses — a predictable consequence of melanocortin activity given MC1R's role in pigmentation.

Regulatory status (2026). Bremelanotide was approved by the U.S. FDA in 2019, marketed as Vyleesi, for the treatment of premenopausal women with acquired, generalized HSDD.¹⁴ That approval does not extend to men, to erectile dysfunction, or to postmenopausal women. Research-grade PT-141 supplied for laboratory use is not an approved drug product and is not intended for human administration. Any experimental work should proceed under the appropriate institutional and ethical oversight.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.